Back to Stocks

BIVI

BIOVIE INC.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

BioVie is strategically leveraging non-dilutive funding to advance its high-potential neuro-inflammatory platform. The company's partnership with the U.S.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative surrounding government grants, BioVie's financial foundation remains precarious.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every BIVI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The latest 10-Q reveals a company at a critical juncture, balancing a high-risk clinical pipeline against a fragile financial base. While the DOD grant provides a temporary lifeline and scientific validation for the Long COVID program, it does not solve the fundamental problem of a pre-revenue company with a high burn rate. The upcoming Parkinson's data in mid-2026 represents a binary event that will likely determine the company's survival or failure. Ultimately, the investment case for BioVie is a trade-off between the potential for a breakthrough in neurodegenerative treatment and the very real possibility of further equity dilution or insolvency. The convergence of pending litigation and the 'going concern' warning suggests that the margin for error is non-existent. Investors must weigh the possibility of a clinical home run against a balance sheet that is struggling to sustain operations through the next catalyst.

Selected Quarter

Core Takeaway

BioVie is utilizing a DOD grant to fund Long COVID research while racing toward a binary Parkinson's data readout, though financial instability persists.

Investor Lens

The trade-off is between a potential mid-2026 clinical breakthrough and the risk of total capital loss due to insolvency or litigation.

Watch Next

Topline results from the Phase 2b 'Sunrise' Parkinson's trial expected in mid-2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.28Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 11

Operating expenses increased 78% year-over-year to $5.4 million in Q1.

margin compression
70%
bearishMay 11

Over 8 million warrants and 2.7 million options create significant overhang.

dilution risk
80%
neutralMay 11

Ongoing securities class action and derivative lawsuits pending in Nevada court.

regulatory action
50%
bullishMay 11

Net proceeds of $10.5 million from August 2025 offering extended runway.

capital raise
40%
bearishMay 11

Operating expenses increased 78% year-over-year to $5.4 million in Q1.

margin compression
70%
bearishMay 11

Over 8 million warrants and 2.7 million options create significant overhang.

dilution risk
80%
neutralMay 11

Ongoing securities class action and derivative lawsuits pending in Nevada court.

regulatory action
50%
bullishMay 11

Net proceeds of $10.5 million from August 2025 offering extended runway.

capital raise
40%

Filing History

10-QMay 11, 2026
Expand Sequence

The latest 10-Q reveals a company at a critical juncture, balancing a high-risk clinical pipeline against a fragile financial base. While the DOD grant provides a temporary lifeline and scientific validation for the Long COVID program, it does not solve the fundamental problem of a pre-revenue company with a high burn rate. The upcoming Parkinson's data in mid-2026 represents a binary event that will likely determine the company's survival or failure. Ultimately, the investment case for BioVie is a trade-off between the potential for a breakthrough in neurodegenerative treatment and the very real possibility of further equity dilution or insolvency. The convergence of pending litigation and the 'going concern' warning suggests that the margin for error is non-existent. Investors must weigh the possibility of a clinical home run against a balance sheet that is struggling to sustain operations through the next catalyst.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.